Results 91 to 100 of about 146,093 (222)

Do angiotensin II type 1 receptor blockers have molecular effects? [PDF]

Hypertension Research, 2009
Shin-Ichiro, Miura, Keijiro, Saku
openaire   +2 more sources

Correction to: Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study [PDF]

, 2019
Satoshi Imaizumi, Yuhei Shiga, Masahiro Ogawa, Hideto Sako, Yoshihisa Nagata, Akira Matsunaga, Tetsuro Shirotani, Fumihiro Hoshino, Eiji Yahiro, Yuko Uehara, Natsumi Morito, Hiroyuki Tanigawa, Dai Shimono, Mikio Fukushima, Hidekazu Sugihara, Kenji Norimatsu, Takaaki Kusumoto, Keijiro Saku, Shin‐ichiro Miura, Shin-ichiro Miura   +19 more
openalex   +1 more source

The Angiotensin II type 1 receptor blocker candesartan suppresses

The Angiotensin II type 1 receptor blocker candesartan suppresses
博士論文要旨Abstract 以下に掲載：cancer letters 355(1) pp.46-53 2014. Elsevier. 共著者：Mitsuyoshi Okazaki , Sachio Fushida, Shinichi Harada, Tomoya Tsukada, Jun Kinoshita, Katsunobu Oyama, Hidehiro Tajima, Itasu Ninomiya, Takashi Fujimura, Tetsuo ...
openaire   +1 more source

Neuroprotective Effects of Angiotensin II Type 1 Receptor Blocker in a Rat Model of Chronic Glaucoma [PDF]

, 2009
Hongwei Yang, Kazuyuki Hirooka, K. Fukuda, Fumio Shiraga   +3 more
openalex   +1 more source

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer

Oncology Reviews, 2011
Angiotensin II (Ang-II) plays a key role as a vasoconstrictor in controlling blood pressure and electrolyte/fluid homeostasis. Recently it has also been shown that this peptide is a cytokine, acting as a growth factor in cardiovascular and stromal cells.
Hiroji Uemura, Hitoshi Ishiguro, Yoshinobu Kubota   +2 more
doaj   +2 more sources

Angiotensin II Type-1 Receptor Blocker Valsartan Enhances Insulin Sensitivity in Skeletal Muscles of Diabetic Mice [PDF]

, 2004
Tetsuya Shiuchi, Masaru Iwai, Huan-Sheng Li, Lan Wu, Li‐Juan Min, Jian‐Mei Li, Midori Okumura, Taixing Cui, Masatsugu Horiuchi   +8 more
openalex   +1 more source

SUPPRESSION OF ADVANCED GLYCATION AND LIPOXIDATION END PRODUCTS BY ANGIOTENSIN II TYPE-1 RECEPTOR BLOCKER CANDESARTAN IN TYPE 2 DIABETIC PATIENTS WITH ESSENTIAL HYPERTENSION

, 2013
Yoshiaki Ōno, Kenji Mizuno, Michihiko Takahashi, Yukio Miura, Tsuyoshi Watanabe   +4 more
openalex   +2 more sources

No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.

Journal of the American Society of Nephrology, 2006
G. Opelz, M. Zeier, G. Laux, C. Morath, B. Döhler   +4 more
semanticscholar   +1 more source

Valsartan in the treatment of heart attack survivors

Vascular Health and Risk Management, 2006
Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaAbstract: Survivors of myocardial infarction (MI) are at high risk of disability and death. This is due to infarct-related complications such as
Bodh I Jugdutt
doaj  

Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway [PDF]

, 2021
Kensuke Hachiya, Masahiro Masuya, Naoki Kuroda, Misao Yoneda, Junya Tsuboi, Keiki Nagaharu, Komei Nishimura, Takuya Shiotani, Kohshi Ohishi, Isao Tawara, Naoyuki Katayama   +10 more
openalex   +1 more source